# Development of PANXEON pancreatic cancer blood test

> Live situation record from CLSTR: https://clstr.news/situations/development-of-panxeon-pancreatic-cancer-blood-test
> Updated: 2026-09-19T00:13:49.000Z. Sources: 14. Developments: 2.

An international research team, led by the US-based City of Hope, has developed PANXEON, an experimental liquid biopsy blood test designed for the early detection of pancreatic ductal adenocarcinoma (PDAC).

Published in the journal Nature Medicine, the study involved nearly 1,800 participants across the United States, Europe, and Asia. The technology utilizes artificial intelligence to analyze a combination of biomarkers, specifically circulating microRNA, exosomal microRNA, and the CA19-9 (or CA 10-9) protein. This combination allows for a more comprehensive risk score than single-biomarker tests.

In clinical testing, the method identified stage 1 and stage 2 pancreatic cancers with approximately 87% accuracy. The test also demonstrated the ability to detect high-grade dysplasia, a precancerous condition, in over 64% of cases. Researchers reported a false positive rate of 3% among low-risk groups and 16% among high-risk groups. The test is intended to serve as a noninvasive complement to current imaging methods, helping to identify high-risk individuals who may require more intensive surveillance or intervention. This innovation aims to transform the management of pancreatic adenocarcinoma, a disease often diagnosed too late for effective treatment.

## Claims

- The study results were published in the journal Nature Medicine. (corroborated by 5 sources)
- The Panxeon test combines microRNA, exosomal microRNA, and the CA 19-9 protein. (corroborated by 5 sources)
- The Panxeon test detected pancreatic cancer in stages 1 and 2 in approximately 87% of cases. (corroborated by 5 sources)
- The test resulted in a false-positive rate of 3% among low-risk individuals. (corroborated by 5 sources)
- The test identified high-grade dysplasia in over 64% of patients with high-risk pancreatic cysts. (corroborated by 5 sources)
- The international study involved approximately 1,800 participants from the US, Europe, and Asia. (corroborated by 5 sources)
- The test utilizes an artificial intelligence algorithm to process molecular markers and calculate a risk score. (corroborated by 5 sources)
- The research was led by City of Hope. (corroborated by 3 sources)

## Timeline

### 2026-09-19: Panxeon blood test detects early-stage pancreatic cancer with 87% accuracy

A new blood test called Panxeon, utilizing AI and three biomarkers, can detect early-stage pancreatic cancer with 87% accuracy, according to a study published in Nature Medicine.

5 sources. https://clstr.news/cluster/panxeon-blood-test-detects-early-stage-pancreatic-cancer-with-87-accuracy-1

### 2026-09-16: City of Hope develops PANXEON blood test for early pancreatic cancer detection

A new blood test called PANXEON, developed by City of Hope, can detect early-stage pancreatic cancer with 87% accuracy using AI and liquid biopsy technology.

9 sources. https://clstr.news/cluster/panxeon-blood-test-detects-early-stage-pancreatic-cancer-with-87-accuracy

---
Cite as: Development of PANXEON pancreatic cancer blood test. CLSTR, https://clstr.news/situations/development-of-panxeon-pancreatic-cancer-blood-test